神経内科外来シリーズ　3　もの忘れ外来

出版社： メジカルビュー社
著者：
発行日： 2016-09-10
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784758303842
シリーズ： 神経内科外来シリーズ
電子書籍版： 2016-09-10 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,700 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,700 円(税込)

購入する

商品紹介

神経内科医が接する機会の多い神経疾患（頭痛、認知症、パーキンソン病、てんかん、脳卒中）の外来診察に必要なノウハウを、シェーマ、フローチャートなどを多用しコンパクトにまとめて解説しているシリーズ。今回は、認知症を取り上げる。「もの忘れ」にはじまる認知症は、その原因は一様ではなく、それに応じて治療にあたらなければならない。本書では、外来で必要な基本的知識、外来の基本的な流れを解説した後、さまざまな認知症を取り上げ、それぞれCase Studyをとおして診察から治療を学べるようになっている。また患者の大部分が高齢者のため、看取りについても取り上げる。認知症診療の基本が身につく1冊である。

目次

  • 神経内科外来シリーズ　3　もの忘れ外来

    ―目次―

    I　もの忘れ外来
    　総論

    II　診察・治療の進め方
    　診断に必要な心理テスト
    　画像診断
    　BPSDに対する薬物療法
    　BPSDに対する非薬物療法
    　認知症の予防
    　高度認知症患者の看取り
    　　―人工的水分・栄養補給法の問題を中心に
    　介護者に対する支援
    　根本治療に向けての創薬
    　
    III　主な認知症の診断と治療
    　軽度認知症（MCI）の診断と治療
    　アルツハイマー病の診断と治療
    　アルツハイマー病の診断と治療
    　　ドネペジルを使う患者、使わない患者
    　アルツハイマー病の診断と治療
    　　メマンチンを使う患者、使わない患者
    　アルツハイマー病の診断と治療
    　　ガランタミンを使う患者、使わない患者
    　アルツハイマー病の診断と治療
    　　リバスチグミンパッチを使う患者、使わない患者
    　レビー小体型認知症の診断と治療
    　脳血管性認知症の診断と治療
    　前頭側頭型認知症の診断と治療
    　特発性正常圧水頭症―Treatable dementia―
    　見逃してはいけない認知症

    IV　社会資源の活用
    　介護保険の導入と利用法
    　新オレンジプラン（認知症施策推進総合戦略）

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

(II) 診察・治療の進め方

P.21 掲載の参考文献
1) 加藤伸司, 下垣光, 他. 改訂長谷川式簡易知能評価スケール (HDS-R) の作成. 老年精神医学雑誌 1991 ; 2 : 1339-47.
Medical*Online
2) Folstein MF, Folstein SE, et al. "Mini-mental state". A Practical method for grading the cognitive state of patients for the clinician. J Psychiatric Research 1975 ; 12 : 189-98.
 
3) 森悦郎, 三谷洋子, 他. 神経疾患患者における日本語版Mini-Mental Stateテストの有用性. 神経心理学 1985 ; 1 : 2-10.
 
4) 山内俊雄・鹿島晴雄総編集. 精神・心理機能評価ハンドブック, 中山書店, 2015.
 
5) 福井俊哉. 症例から学ぶ戦略的認知症診断, 南山堂, 2007.
 
6) 田川皓一編. 神経心理学評価ハンドブック, 西村書店, 2004.
 
7) 穴水幸子, 若松直樹, 他. 臨床編 VI. 痴呆の評価, 認知機能障害の個別的評価に関する神経心理学的検査, 記憶障害, Rey-Osterrieth Complex Figure Test (ROCFT). 日本臨床 2003 ; 増刊号 9 : 285-90.
 
8) 今村陽子. 臨床高次脳機能評価マニュアル, 新興医学出版社, 2000.
 
9) Yokoi K, Nishio Y, et al. Hallucinators find meaning in noises : Pareidolic illusions in dementia with Lewy bodies. Neuropsychologia 2014 ; 56 : 245-54.
PubMed
10) 目黒健一. 痴呆の臨床, 医学書院, 2004.
 
P.33 掲載の参考文献
1) Fotenos AF, Snyder AZ, Girton LE, et al. Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology 2005 ; 64 : 1032-39.
 
2) Ohnishi T, Matsuda H, Tabira T, et al. Changes in brain morphology in Alzheimer disease and normal agin : is Alzheimer disease and exaggerated agig process? AJNR Am J Neuroradiol 2001 ; 22 : 1680-85.
 
3) 松田博史. 早期アルツハイマー型認知症診断支援システムVSRADについて. 日放技学誌 2006 ; 62 : 1066-72.
 
4) Whitewell JL, Weigand SD, Shiung MM, et al. Focal atrophy in dementia with Lewy bodies on MRI : a distinct pattern from Alzheimer's disease. Brain 2007 ; 130 : 708-19.
 
5) 足立正, 斎藤祐子, 徳丸阿耶, 他. 嗜銀顆粒性疾患の左右差と臨床画像診断. 臨床神経 2009 ; 49 : 1011.
 
6) Matsusue E, Sugihara S, Fujii S, et al. Cerebral cortical and white matter lesions in amyotroophic lateral sclerosis with dementia : correlation with MR and phthologic examinations. AJNR Am J Neuroradiol 2007 ; 28 : 1505-10.
PubMed
7) Mori H, Yagishita A, Takeda T, et al. Symmetric temporal abnormalities on MR imaging in amyotrophic lateral sclerosis with dementia. AJNR Am J Neuroradiol 2007 ; 28 : 1511-6.
PubMed
8) Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005 ; 64 : 2050-5.
PubMed
9) Demaerel P, Heiner L, Robberecht W, et al. Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease. Neurology 1999 ; 52 : 205-8.
PubMed
10) Bahn MM, Parchi P. Abnormal diffusion-weighted magnestic-resonance images in Creutzfelt-Jakob disease. Arch Neurol 1999 : 577-83.
 
11) Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm 2000 ; Suppl 59 : 23-30.
 
12) Ishii K, Minoshima S. PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease. Eur J Nucl Med Mol Imaging 2005 ; 32 : 1463-5.
PubMed
13) Minoshima S, Foster NL, Kuhl DE. Posterior cingulated cortex in Alzheimer's disease. Lancet 1994 ; 344 : 895.
PubMed
14) Matsuda H, Mizumura S, Nagao T, et al. Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. AJNR Am J Neuroradiol 2007 ; 28 : 731-6.
PubMed
15) 天野隆弘, 佐々木貴浩. 3D-SPECTによるAlzheimer病の特異的診断. 医学の歩み 1998 ; 187 (2) : 129-30.
 
16) Holmes C, Cairns N, Lantos P, et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999 ; 174 : 45-50.
PubMed
17) Minoshima S, Foster NL, Sima AA, et al. Alzheimer's disease versus dementia with lwy bodies : cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001 ; 50 : 358-65.
 
18) Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer' disease : a PET follow-up study. Eur J Nucl Med Mol Imaging 2003 ; 30 : 1104-13.
PubMed
19) Lim SM, Katsifis A, Villemagne VL, et al. The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-b-CIT SPECT for Diagnosis of Dementia with Lewy Bodies. J Nucl Med 2009 ; 50 : 1638-45.
 
20) McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium. Neurology 2005 ; 65 : 1863-72.
PubMed
21) 天野隆弘, 佐々木貴浩. 3D-SPECTによるAlzheimer病の特異的診断. 医学の歩み 1998 ; 187 : 129-30.
 
22) 厚生労働科学研究費補助金長寿科学総合研究事業. ICD-10 分類に準拠した脳血管性痴呆に関する研究 (主任研究者 長田乾). 平成17年度総括研究報告書. 2006.
 
23) McKeith IG, Dickson DW, Lowe J, et al : third report of the DLB Consortium. Neurology 2005 ; 65 (12) : 1863-72.
PubMed
24) McKeith I, O'Brien J, Walker Z, et al ; DLBStudy Group. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies : a phase III, multicentre study. Lancet Neurol 2007 ; 6 (4) : 305-13.
PubMed
25) Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies : a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007 ; 78 (11) : 1176-81.
PubMed
26) Roselli F, Pisciotta NM, Perneczky R, et al. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies : a 123I-FP-CIT SPECT study. Mov Disord 2009 ; 24 (14) : 2097-103.
PubMed
27) Ziebell M, Andersen BB, Pinborg LH, et al. Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. J Nucl Med 2013 ; 54 (7) : 1072-6.
 
28) Siepel FJ, Rongve A, Buter TC, et al. (123I) FP-CIT SPECT in suspected dementia with Lewy bodies : a longitudinal case study. BMJ Open 2013 ; 3 (4).
PubMed
29) O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004 ; 61 : 919-25.
PubMed
30) 心臓核医学検査ガイドライン.
 
31) Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 : 280-92
 
32) アミロイドPETイメージング剤合成装置の適正使用ガイドライン.
 
33) Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004 ; 55 : 306-19.
PubMed
34) Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittburgh Compound-B. J Cereb Blood Flow Metab 2005 ; 25 : 1528-47.
 
35) Minoshima S, Sasaki T, Petrie E. Fluorodeoxyglucose PET Imaging of Dementia : Principles and Clinical Applications. In ; Wahl RL, ed. Principles and practice of PET and PET/CT, Lippincott Williams & Wilkins, 2009, p500-15.
 
36) 橋本順, 佐々木貴浩. 脳血流SPECTによる認知症の鑑別診断. 臨床放射線 2010 ; 55 : 1386-407.
 
P.43 掲載の参考文献
1) 厚生労働省 : http://www.mhlw.go.jp/stf/houdou/2r98520000036k0c.html
 
2) van Iersel MB, Zuidema SU, Koopmans RT, et al. Antipsychotics for behavioural and psychological problems in elderly people with dementia : a systematic review of adverse events. Drugs Aging 2005 ; 22 (10) : 845-58.
PubMed
3) Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies : a randomized, placebo-controlled trial. Ann Neurol 2012 ; 72 (1) : 41-52.
PubMed
4) Ukai K, et al. Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies. Psychogeriatrics 2014, DOI : 10.1111/psyg.12089
 
5) Iwasaki K, Kosaka K, Mori H, et al. Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine. Psychogeriatrics 2012 ; 12 (4) : 235-41.
PubMed
6) Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002 ; 14 (4) : 389-404.
PubMed
P.52 掲載の参考文献
1) Fujii M, et al. Emotional function in dementia patients. Psychogeriatrics 2014 ; 14 : 202-9.
PubMed
2) Fujii M, et al. Hypothesis of behavioral and psychological symptoms of dementia. Psychogeriatrics 2010 ; 10 : 113-6.
PubMed
3) Matsuda H, et al. Coffee therapy for patients with behavioral and psychological symptoms of dementia. Geriatr Gerontol Int 2012 ; 12 : 568-70.
PubMed
4) Butler JP, et al. New lessons of nurturing life for geriatric patients. Tohoku J Exp Med 2012 ; 227 : 203-10.
PubMed
5) Kaneko Y, et al. Efficacy of white noise therapy for dementia patients with schizophrenia. Geriatr Gerontol Int 2013 ; 13 : 808-9.
PubMed
6) Satoh S, et al. Rivastigmine patch and massage for Alzheimer's disease patients. Geriatr Gerontol Int 2013 ; 13 : 515-6.
PubMed
7) Fujii M, et al. Mini-Emotional State Examination for dementia patients. Geriatr Gerontol Int 2014 ; 14 : 508-13.
PubMed
8) Maeda Y, et al. Emotional Satisfaction Index for dementia patients. Geriatr Gerontol Int (in press).
 
9) Maeda Y, et al. Dramatic emotional therapy for dementia patients. Psychogeriatrics 2015 ; 15 : 277-8.
PubMed
10) Fujii M, et al. Identity of geriatric medicine. Geriatr Gerontol Int (in press).
 
P.62 掲載の参考文献
1) 厚生労働省ホームページ. 平成25年国民生活基礎調査の概況 ; IV. 介護の状況 ; 2. 要介護者等の状況. http://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa13/dl/16.pdf
 
2) Wilson D, Peter R, et al. Last advances on interventions that may prevent, delay or ameliorate dementia. Ther Adv Chronic Dis 2011 ; 2 : 161-73.
PubMed
3) Laurin D, Verreault R, et al. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 2001 ; 58 : 498-504.
PubMed
4) Yoshitake T, Kiyohara T, et al. In Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population ; The Hisayama Study. Neurology 1995 ; 45 : 1161-8.
 
5) Lazarov O, Robinson J, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005 ; 120 : 701-13.
PubMed
6) Neeper SA, Gomez-Pinilla F, et al. Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res 1996 ; 726 : 49-56.
PubMed
7) Cotman CW, Engesser-Cesar C : Exercise enhances and protects brain function. Exerc Sport Sci Rev 2002 ; 30 : 75-9.
PubMed
8) Maki Y, Ura C, et al. Effects of intervention Using a community-based walking program for prevention of mental decline : a randomized controlled trial. J Am Geriatr Soc 2012 ; 60 : 505-10.
PubMed
9) Lautenschlager NT, Cox KL, et al. Effect of physical activity on cognitive function in older Adults at risk for Alzheimer disease ; A randomized trial. JAMA 2008 ; 300 : 1027-37.
PubMed
10) Kalmijn S, Launer LJ, et al. Dietary fats intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 1997 ; 42 : 776-82.
PubMed
11) Giselle P, Lim GP, et al : A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model. J Neurosci 2005 ; 25 : 3032-40.
 
12) Lindsay J, Laurin D, et al. Risk factors for Alzheimer's disease : A prospective analysis from the Canadian study of health and aging. Am J Epidemiol 2002 ; 156 : 445-53.
PubMed
13) Morris MC, Evans DA, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002 ; 287 : 3230-7.
 
14) Scarmeas N, Stern Y, et al. Mediterranean diet, Alzheimer disease, and Vascular mediation. Arch Neurol 2006 ; 63 : 1709-17.
PubMed
15) Valls-Pedret C, Sala-Vila A, et al. Mediterranean Diet and Age-Related Cognitive Decline : A Randomized Clinical Trial. JAMA 2015 ; 175 : 1094-103.
PubMed
16) Ozawa M, Ninomiya T, et al. Dietary patterns, risk of dementia in an elderly Japanese population : the Hisayama Study. Am J Clin Nutr 2013 ; 97 : 1076-82.
 
17) Wilson RS, Mendes De Leon CF, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 2002 ; 287 : 742-48.
PubMed
18) Willis SL, Tennstedt SL, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA 2006 ; 296 : 2805-2814.
PubMed
19) Bickel H, Kurz A. Education, occupation, and Dementia ; The bavarian school sisters study. Dement Geriatr Cogn Disord 2009 ; 27 : 548-56.
PubMed
20) Kempermann G, Gast D, et al. Neuroplasticity in old age ; Sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment. Ann Neurol 2002 ; 52 : 135-43.
PubMed
21) Kondo K, Niino M, et al. A case-control study of Alzheimer's disease in Japan-significance of life-styles. Dementia 1994 ; 5 : 314-26.
PubMed
22) Fratiglioni L, Wang HX, et al. Influence of social network on occurrence of dementia ; a community-based longitudinal study. Lancet 2000 ; 355 : 1315-9.
PubMed
23) 厚生労働省ホームページ. 介護予防マニュアル (改訂版 : 平成24年3月) 「第7章 認知機能低下 予防・支援マニュアル」参考資料 7-4「習慣化したい人のためのウォーキングプログラムテキスト改訂版」http://www.mhlw.go.jp/topics/2009/05/dl/tp0501-sankou7-4.pdf
 
24) Maki Y, Ura C, et al. Intervention using a community-based walking program is effective for elderly adults with depressive tendencies. J Am Geriatr Soc 2012 ; 60 : 1590-1.
PubMed
P.73 掲載の参考文献
1) 荒井啓行. 認知症. 『老年医学系統講義テキスト』 (日本老年医学会編), 西村書店, 2013, pp257-65.
 
2) 会田薫子. 認知症末期患者に対する人工的水分・栄養補給法の施行実態とその関連要因に関する調査から. 日本老年医学会雑誌 2012 ; 49 : 71-4.
 
3) Aita K, et al. Physicians' attitudes about artificial feeding in older patients with severe cognitive impairment in Japan : A qualitative study. BMC Geriatrics 2007 ; 7 : 22.
PubMed
4) 会田薫子. 延命医療と臨床現場-人工呼吸器と胃ろうの医療倫理学. 東京大学出版会, 2011, pp47-223.
 
5) 石束嘉和. 高度アルツハイマー型認知症についてどう考えるか. Clinician 2007 ; 87 : 1141-4.
 
6) Australian government national health and medical research council. Guidelines for a palliative approach in residential aged care. Enhanced version-May 2006. http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/pc29.pdf
 
7) Printz LA. Is withholding hydration a valid comfort measure in the terminally ill? Geriatrics 1988 ; 43 : 84-8.
PubMed
8) Ahronheim JC. Nutrition and hydration in the terminal patient. Clinics in Geriatric Medicine 1996 ; 12 : 379-91.
PubMed
9) 植村和正. 高齢者の終末期医療の特徴. これからの老年学 (井口昭久編), 名古屋大学出版会, 2000, pp302-5.
 
10) American Geriatrics Society : Feeding Tubes in Advanced Dementia Position Statement. 2013 May. http://www.americangeriatrics.org/files/documents/feeding.tubes.advanced.dementia.pdf
 
11) 日本老年医学会. 高齢者の終末期の医療およびケア」に関する日本老年医学会の「立場表明」. 日本老年医学会雑誌 2012 ; 49 : 381-6.
 
12) 日本老年医学会. 高齢者ケアの意思決定プロセスに関するガイドライン-人工的水分・栄養補給の導入を中心として. 2012. http://www.jpn-geriat-soc.or.jp/info/topics/pdf/jgs_ahn_gl_2012.pdf
 
13) 会田薫子. 患者の意思を尊重した医療およびケアとは-意思決定能力を見据えて. 日本老年医学会雑誌 2013 ; 50 : 487-90.
 
14) 清水哲郎. 生物学的 <生命> と物語られる <生> -医療現場から. 哲学 2002 ; 53 : 1-14.
 
15) 会田薫子. 胃ろうの適応と臨床倫理-一人ひとりの最善を探る意思決定のために. 日本老年医学会雑誌 2012 ; 49 : 130-9.
 
16) 清水哲郎. 臨床倫理エッセンシャルズ. 東京大学大学院人文社会系研究科死生学・応用倫理センター上廣講座臨床倫理プロジェクト, 2012.
 
17) 厚生労働省. 人生の最終段階における医療の決定プロセスに関するガイドライン. 2007. http://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000078981.pdf
 
18) 清水哲郎, 会田薫子 : 高齢者ケアと人工栄養を考える-本人・家族のための意思決定プロセスノート. 医学と看護社, 2013.
 
P.85 掲載の参考文献
1) 本間昭. 認知症ケアの視点. 認知症ケア標準テキスト改訂・認知症ケアの実際 I : 総論 (株) ワールドプラニング, 2009, p3.
 
2) 認知症の人と家族の会ホームページ http://www.alzheimer.or.jp/
 
3) 朝田隆. 施設の事例で学ぶ認知症のある人の生活障害へのアプローチ. 高齢者安心安全ケア 実践と記録 2015 ; 12 (3) : 32.
 
4) 六角僚子. 認知症ケアの考え方と技術. 東京, 医学書院, 2005, p30-3.
 
5) Christine Boden, 桧垣陽子訳. 私は誰になっていくの? クリエイツかもがわ 2003, p75.
 
6) 牧野史子. ケアラーを支えるために. 老年精神医学雑誌 2014 ; 第25巻 : p975-83.
 
P.97 掲載の参考文献
1) Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976 ; 2 : 1403.
PubMed
2) Perry PK, Gibson PH, Blessed G, et al. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic. J Neurol Sci 1977 ; 34 : 247-65.
 
3) Sugimoto H, Tsuchiya Y, et al. Novel piperidine derivatives. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4- [2- (N-benzoylamino) ethyl] piperidine derivatives. J Med Chem 1990 ; 33 : 1880.
PubMed
4) Sugimoto H, Iimura Y, et al. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors : 1-benzyl-4- ([5,6-dimethoxy-1-oxoindan-2-yl) methyl] piperidine hydrochloride and related compounds. J Med Chem 1995 ; 38 : 4821-9.
PubMed
5) Rogers SL, Farlow MR, Doody RS, et al. Neurology 1998 ; 50 : 136-45.
PubMed
6) Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower A β42 in vivo. J Clin Invest 2003 ; 112 (3) : 440-9.
 
7) Yi P, Hadden C, Kulanthaivel, et al. Disposition and metabolism of semagacestat, a{gamma}-secretase inhibitor, in humans. Drug metabolism and disposition : the biologicalfate of chemicals 2010 ; 38 : 554-65.
 
8) Mikulca JA, Nguyen V, et al. Potential novel targets for Alzheimer pharmacotherapy : II. Update on secretase inhibitors and related approaches. J Clin Pharm Ther 2014 Feb ; 39 (1) : 25-37. doi : 10.1111/jcpt.12112. Epub 2013 Dec 8. Review.
 
9) Bayer AJ, Bullock R, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005 Jan 11 ; 64 (1) : 94-101.
PubMed
10) Harrington CR, Storey JM, et al. Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease. J Biol Chem 2015 24 ; 290 : 10862-75.
 

(III) 主な認知症の診断と治療

P.113 掲載の参考文献
1) Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment : clinical characterization and outcome. Arch Neurol 1999 ; 56 (3) : 303-8.
PubMed
2) Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease : Recommendations from the National Institute on Aging and Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 2011 ; 7 (3) : 270-9.
PubMed
3) Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease : Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's Dement 2011 ; 7 (3) : 280-92.
PubMed
4) DSM-5 精神疾患の診断・統計マニュアル, 医学書院, 2014, 596.
 
5) Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia : A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2011 ; 42 (9) : 2672-713.
PubMed
6) Mariani E, Monastero R, Mecocci P. Mild cognitive impairment : a systematic review. J Alzheimers Dis 2007 ; 12 (1) : 23-35.
PubMed
7) 朝田隆. 厚生労働科学研究費補助金 (認知症対策総合研究事業) 都市部における認知症有病率と認知症の生活機能障害への対応. 平成23～24年度総合研究報告書, 2013.
 
8) Manly JJ, Tang M-X, Schupf N, Stern Y, et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 2008 ; 63 (4) : 494-506.
 
9) Fischer P, Jungwirth S, Zehetmayer S, et al. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 2007 ; 68 (4) : 288-91.
PubMed
10) 齊藤祐子, 村山繁雄. 病理学的観点からの軽度認知機能障害. Modern Physician 2006 ; 26 (12) : 1889-92.
 
11) Markesbery WR, Schmitt FA, Kryscio RJ, et al. Neuropathologic Substrate of Mild Cognitive Impairment. Arch Neurol 2006 ; 63 (1) : 38-46.
PubMed
12) Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 2004 ; 16 (2) : 129-40.
PubMed
13) Gainotti G, Quaranta D, Vita MG, Marra C. Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 2014 ; 38 (3) : 481-95.
PubMed
14) Peres K, Chrysostome V, Fabrigoule C, et al. Restriction in complex activities of daily living in MCI : impact on outcome. Neurology 2006 ; 67 (3) : 461-6.
PubMed
15) Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease : a PET follow-up study. Eur J Nucl Med Mol Imaging 2003 ; 30 (8) : 1104-13.
PubMed
16) Hirao K, Ohnishi T, Hirata Y, et al. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 2005 ; 28 (4) : 1014-21.
PubMed
17) Koepsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near-normal cognition : Risk factors and prognosis. Neurology 2012 ; 79 (15) : 1591-8.
PubMed
18) Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI : A 48-week randomized, placebo-controlled trial. Neurology 2009 ; 72 (18) : 1555-61. doi : 10.1212/01.wnl.0000344650.95823.03.
 
19) Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005 ; 352 (23) : 2379-88. doi : 10.1056/NEJMoa050151.
 
20) Suzuki T, Shimada H, Makizako H, et al. A Randomized Controlled Trial of Multicomponent Exercise in Older Adults with Mild Cognitive Impairment. Aleman A, editor. PLoS One 2013 ; 8 (4) : e61483.
 
21) 本間昭, 福沢一吉, 塚田良雄, 他. Alzheimer's Disease Assessment Scale (ADAS) 日本版の作成. 老年精神医学雑誌 1992 ; 3 (6) : 647-55.
Medical*Online
22) 認知症疾患治療ガイドライン作成合同委員会. 日本神経学会 (監修), 認知症疾患治療ガイドライン 2010, 医学書院, 2010.
 
P.131 掲載の参考文献
1) Wada-Isoe K, Uemura Y, et al. Prevalence of Dementia and Mild Cognitive Impairment in the Rural Island Town of Ama-cho. Japan Dement Geriatr Cogn Dis Extra 2012 ; 2 : 190-9.
PubMed
2) Tang-Wai DF, Graff-Radford NR, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004 ; 63 : 1168-74.
PubMed
3) Gorno-Tempini ML, Brambati SM, et al. The logopenic/phonological variant of primary progressive aphasia. Neurology 2008 ; 71 : 1227-34.
PubMed
4) 認知症疾患治療ガイドライン作成合同委員会. 認知症疾患治療ガイドライン 2010, 医学書院, 東京, 2010.
 
5) American Psychiatric Association日本精神神経学会 (日本語版用語監修) : DSM-5 精神疾患の診断・統計マニュアル.
 
6) McKhann GM, Knopman DS, et al. The diagnosis of dementia due to Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 : 263-9.
PubMed
7) 日本神経学会 "認知症疾患治療ガイドライン" 作成合同委員会. 認知症疾患治療ガイドライン 2010 コンパクト版 2012, 医学書院, 東京, 2012.
 
8) 認知症, 特にBPSDへの適切な薬物使用に関するガイドライン作成に関する研究班. かかりつけ医のためのBPSDに対応する向精神薬使用ガイドライン. www.mhlw.go.jp/file.jsp?id=130724
 
P.139 掲載の参考文献
1) 田北昌史. 最近の認知症治療薬の薬理と臨床 1. 「アリセプト」について. 東京心のクリニック増刊号, 一般社団法人東京精神神経科診療所協会, 東京, 2013, 18-22.
 
2) 田北昌史. 認知症の原因となる, あるいは認知症を増悪させる薬剤は? j med No.11 いきなり名医! 日常診療で診る・見守る認知症, 日本医事新報社, 東京, 2010 ; 83-6.
 
3) 繁田雅弘. ドネペジル (アリセプト(R)) は "興奮" させる薬剤か? CLINICIAN, エーザイ (株), 東京, 2012 ; 608 : 382-5.
 
4) 川畑信也. 病歴ではアルツハイマー型認知症を考えるのですが, HDS-Rでは好成績を示す患者さんがいます. どう診断したらよいでしょうか? 治療特別編集 認知症でお困りですか? 南山堂, 東京, 2013 ; 16-8.
 
5) 浦上克哉. かかりつけ医・非専門医が通常の外来でアルツハイマー型認知症を診断する際の診療のコツを教えて下さい. 治療特別編集 認知症でお困りですか? 南山堂, 東京, 2013 ; 2-6.
 
P.147 掲載の参考文献
1) Wilcock GK,et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease : a pooled analysis of 3 studies. JClin Psychiatry 2008 ; 69 (3) : 341-8.
 
2) メマンチン承認評価資料. 海外第III相臨床試験 (ドネペジル塩酸塩併用)
 
3) Lopez OL, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009 ; 80 (6) : 600-7.
PubMed
4) Ihalainen J, et al. Effects of memantine and donepezil on cortical and hippocampal acetylcholine levels and object recognition memory in rats. Neuropharmacology 2011 ; 61 (5-6) : 891-9.
 
P.155 掲載の参考文献
1) 日本薬剤師研修センター新薬承認情報集 (1999)
 
2) Yano K, et al. Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic Ach receptors in mice. Br J Pharmacol 2009 ; 156 (1) : 173-80.
PubMed
3) Shearman E, et al. Changes in Ceebral Neurotransmitters and Metabolites Induced by Acute Donepezil and Memantine Administrations : A Microdialysis. Brain Res Bull 2006 ; 69 (2) : 204-13.
 
4) Santos M, et al. The Nicotinic Allosteric Potentiating Ligand Galantamine Facilitates Synaptic Transmission in the Mammalian Central Nervous System. Mol Pharmacol 2002 ; 61 (5) : 1222-34.
PubMed
5) Zhang L, Zhou F-M, Dani J-A. Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release. Mol Pharmacol 2004 ; 66 (3) : 538-44.
PubMed
6) Liang Y-Q, Tang X-C. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepi nephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacol sinica 2006 ; 27 (9) : 1127-36.
 
7) Sharp BM, Yatsula M, Fu Y. Effects of galantamine, a nicotinic allosteric potentiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats. J Pharmcol Exp Ther 2004 ; 309 (3) : 1116-23.
 
8) Luigia T, et al. in vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus. Brain Research 2000 ; 865 : 268-71.
 
9) Birgitte R, et al. Serotonin depletion results in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus. Brain Research 2006 ; 1073-1074 : 262-8.
 
10) 馬場康彦. アルツハイマー病に対するガランタミンの臨床効果. Geriatric Medicine 2012 ; 50 (3) : 339-42.
Medical*Online
11) Bonnie D, Kay S. Circadian Cholinergic Rhythms : Implications for Cholinesterase Inhibitor Therapy. Dement Geriatr Cogn Disord 2006 ; 21 : 120-9.
 
P.161 掲載の参考文献
1) Nakamura Y, et al. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra 2011 ; 1 : 163-79.
 
2) 工藤千秋, 他. 貼付型アルツハイマー型認知症治療薬リバスチグミンパッチの認知機能とADLに及ぼす長期的効果. 老年精神医学 2013 ; 24 : 701-4.
Medical*Online
3) Kobayashi H, et al. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease : a Bayesian network meta-analysis. Int J Geriatr Psychiatry 2016 ; 31 : 892-904.
PubMed
4) 降矢芳子, 他. 認知症患者におけるrivastigmineの食欲及び各種ホルモンへの影響. Dementia Japan 2015 ; 29
 
5) Moon M, et al. Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-β 1-42oligomer-injected mice. J Alzheimer's Disease 2014 ; 23 : 147-59.
 
6) Wang H-F, et al. Efficacy and safety of chorinnesterase inhibitors and mematine in cognitive impairment in Parkinson's disease dementia, and dementia with Lewy bodies : systematic review with meta-analysis and toraial sequential analysis. J Neuro Neurosurg Psychiatry 2015 ; 86 : 135-43.
 
P.173 掲載の参考文献
1) 朝田隆 : 都市部における認知症有病率と認知症の生活機能障害への対応. 厚生労働科学研究費補助金認知症対策総合研究事業 平成23-24年度総合研究報告書. 2013.
 
2) McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium. Neurology 2005 ; 65 : 1863-72.
PubMed
3) 高橋晶, 水上勝義, 朝田隆. レビー小体型認知症 (DLB) の前駆症状, 初期症状. 老年精神医学雑誌 2011 ; 22 (増刊I) : 60-4.
 
4) Boeve BF. Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease. Parkinsonism and Related Disorders 2012 ; 18S1 : S41-4.
 
5) Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB) : Frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr 2008 ; 46 : 101-6.
PubMed
6) Ballard C, Johnson M, Piggott M, et al. A positive association between 5HT re-uptake binding sites and depression in dementia with Lewy bodies. J Affect Disord 2002 ; 69 : 219-23.
 
7) Yoshita M, Arai H, Arai H, Arai T, et al. Diagnostic accuracy of cardiac sympathetic imaging with 123I-MIBG myocardial scintigraphy in dementia with Lewy bodies : a multicenter study. PLoS One 2015 ; 10 (3) : e0120540.
PubMed
8) Takahashi S, Mizukami K, Yasuno F, Asada T. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics 2009 ; 9 : 56-61.
PubMed
9) Sweet RA, Hamilton RL, Butters MA, Mulsant BH, et al. Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology 2004 ; 29 : 2242-50.
PubMed
10) Iritani S, Tsuchiya K, Arai T, Akiyama H, et al. An atypical autopsy case of Lewy Body disease with clinically diagnosed major depression : A clinical, radiological and pathological study. Neuropathology 2008 ; 28 : 652-9.
PubMed
11) Takahashi S, Mizukami K, Arai T, Ogawa R, et al. Ventilatory response to hypercapnia predicts dementia with Lewy bodies in late-onset major depressive disorder. Journal of Alzheimer's Disease. 2015 (in press).
 
12) 水上勝義. 老年期うつ病. 認知症の最新医療 2011 ; 1 (3) : 106-11.
Medical*Online
13) Fujishiro H, Iseki E, Nakamura S, Kasanuki K, et al. Dementia with Lewy bodies : early diagnostic challenges. Psychogeriatrics 2013 ; 13 : 128-38.
PubMed
14) Mori E, Ikeda M, Kosaka K, et al. Donepezil for dementia with Lewy bodies : a randomized, placebo-controlled trial. Donepezil-DLB Study Investigators. Ann Neurol 2012 ; 72 (1) : 41-52.
 
15) McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies : a randomised, double-blind, placebo-controlled international study. Lancet 2000 ; 356 (9247) : 2031-6.
 
16) Iwasaki K, Kosaka K, Mori H, et al. Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine. Psychogeriatrics 2012 ; 12 (4) : 235-41.
PubMed
17) Walker Z, Grace J, Overshot R, et al. Olanzapine in dementia with Lewybodies : a clinical study. Int J Geriatr Psychiatry 1999 ; 14 : 459-66.
 
18) Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007 ; 68 (17) : 1356-63.
PubMed
19) 水上勝義, 畑中公孝, 田中芳郎, 朝田隆. 精神症状や行動障害に抑肝散が効果的であったアルツハイマー型認知症の5例. 日本東洋医学雑誌 2006 ; 57 : 655-60.
 
20) 水上勝義, 畑中公孝, 田中芳郎, 朝田隆. 認知症にみられる周辺症状に対する抑肝散の効果について-17自験例の検討から-. 漢方医学 2009 ; 33 (3) : 419-22.
 
P.190 掲載の参考文献
1) Corelick PB, Scuteri A, Black SE, et al. American Heart Association Stroke Council. Council on Epidemiology and Prevention. Council on Cardiovascular Nursing. Council on Cardiovascular Radiology and Intervention. And Council on Cardiovascular Surgery and Anesthesia : Vascular contributions to cognitive impairment and dementia : a statement for healthcare professionals from American Heart Association/American Stroke Association. Stroke 2011 ; 42 : 2672-713.
 
2) Roman GC, Taremichi TK, Erkinjunti T, et al. Vascular dementia diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993 ; 43 : 250-60.
 
3) Kalaria RN. Cerebrovascular disease and mechanisms of cognitive impairment : evidence from clinicopathological studies in humans. Stroke 2012 ; 43 : 2526-34.
PubMed
4) Iadecola C. The pathobiology of vascular dementia. Neuron 2013 ; 80 : 844-66.
PubMed
5) Hachinski VC, Bowler JV. Vascular dementia. Neurology 1993 ; 43 : 2159-60.
PubMed
6) Viswanathan A. Vascular risk factors and dementia. Neurology 2009 ; 72 : 368-74.
PubMed
7) Hachinski VC, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006 ; 37 : 2220-41.
 
8) Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011 ; 42 : 2672-713.
PubMed
9) Dufouil C, Godin O, Chalmers J, et al. Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke 2009 ; 40 : 2219-21.
PubMed
10) Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke. Mild cognitive impairment, dementia, and mortality : the Framingham Offspring Study. Stroke 2010 ; 41 : 600-6.
PubMed
11) Mosley TH Jr, Knopman DS, Catellier DJ, et al. Cerebral MRI findings and cognitive functioning : the Atherosclerosis Risk in Communities study. Neurology 2005 ; 64 : 2056-62.
PubMed
12) Ringelstein EB, Klenffner I, Dittrich R, et al. Hereditary and non-hereditary microangiopathies in young. An up-date. J Neurol Sci 2010 ; 299 : 81-5.
 
13) Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives regarding late-life dementia. Nat Rev Neurol 2009 ; 5 : 649-58.
PubMed
14) Deschaintre Y. Treatment of vascular risk factor's in associated with slower decline in Alzheimer disease. Neurology 2009 ; 73 : 674-680.
 
15) PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 ; 358 : 1033-41.
PubMed
16) Skoog I, Lithell H, Hansson L, et al. Effect of baseline cognitive and antihypertensive treatment on cognitive and cardiovascular outcomes : Study on Cognition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005 ; 18 : 1052-9.
PubMed
17) Peters R, Beckett N, Forette F, et al. for the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly cognitive function assessment (HYVET-COG) : a double-blind, placebo controlled trial. Lancet Neurol 2008 ; 7 : 683-9.
PubMed
18) Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. for the SPARCL investigators. High-dose atrovastatin after stroke or transient ischemic attak. N Engl J Med 2006 ; 355 : 549-59.
 
19) Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients : subanalysis of JELIS trial. Stroke 2008 ; 39 : 2052-8.
PubMed
20) Wilcox R, Bousser MG, Betteridge DJ, et al. Effect of pioglitazone in patients with type 2 diabetes with or without previous stroke : results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007 ; 38 : 865-73.
PubMed
21) Ihara M, Nishino M, Taguchi A, et al. Cilostazol add-on therapy in patients with mild dementia receiving donepezil ; a retrospective study. PLoS One 2014 ; 9 : e89516.
PubMed
22) Shinohara Y, Katayama Y, Uchiyama S. et al. Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010 ; 9 : 959-68.
PubMed
23) Maki T, Okamoto Y, Carare RO, et al. Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid. Ann Clin Transl Neurol 2014 ; 1 : 519-33.
 
24) Shinohara Y : Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. Cerebrovasc Dis 2006 ; 22 : 57-60.
PubMed
25) Tomimoto H, Akiguchi I, Soenaga T, et al. Alternations of the blood-brain barrier and glial cells in white matter lesions in cerebrovascular and Alzheimer's disease patients. Stroke 1996 ; 27 : 2069-74.
 
26) 日本高血圧学会高血圧治療ガイドライン作成委員会編, 日本高血圧学会監修. 第6章 臓器障害を合併する高血圧 POINT6a 脳血管障害. 高血圧治療ガイドライン 2014, ライフサイエンス出版, 東京, 2014, p58-63.
 
27) 日本高血圧学会高血圧治療ガイドライン作成委員会編, 日本高血圧学会監修. 第9章 認知症. 高血圧治療ガイドライン 2014, ライフサイエンス出版, 東京, 2014, p97.
 
28) Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia : a randomized placebo-controlled study. Neurology 2003 ; 61 : 479-86.
PubMed
29) 小川彰, 出江伸一, 鈴木則宏, 他. 日本脳卒中学会脳卒中ガイドライン委員会編. 脳卒中治療ガイドライン 2015, 協和企画, 東京, 2015.
 
P.204 掲載の参考文献
1) Bang J, et al. Frontotemporal dementia. Lancet 2015 ; 386 : 1672-82.
PubMed
2) Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology 2011 ; 76 : 1006-14.
PubMed
3) Li YQ, et al. Frontotemporal Lobar Degeneration : Mechanisms and Therapeutic Strategies. Mol Neurobiol 2015 (Epub ahead of print).
 
4) Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011 ; 134 : 2456-77.
PubMed
5) 尾籠晃司, 飯田仁志. 前頭側頭型認知症FTD (bvFTD) の新たな国際診断基準と問題点. Dementia Japan 2015 ; 29 : 131-8.
 
6) Dubois B, et al. The FAB : a Frontal Assessment Battery at bedside. Neurology 2000 ; 55 : 1621-6.
PubMed
7) Kertesz A, et al. Frontal behavioral inventory : diagnostic criteria for frontal lobe dementia Can J Neurol Sci 1997 ; 24 : 29-36.
PubMed
8) Neary D, et al. Frontotemporal lobar degeneration : a consensus on clinical diagnostic criteria. Neurology. 1998 ; 51 : 1546-54.
PubMed
9) Moretti R, et al. Frontotemporal dementia : paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 2003 ; 49 : 13-9.
PubMed
10) Lebert F, et al. Frontotemporal dementia : a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004 ; 17 : 355-9.
PubMed
11) Pachalska M, et al. Differential diagnosis of behavioral variant of fronto-temporal dementia (bvFTD). Med Sci Monit 2011 ; 17 : CR311-21.
PubMed
12) Manoochehri M, Huey ED. Diagnosis and management of behavioral issues in frontotemporal dementia. Curr Neurol Neurosci Rep 2012 ; 12 : 528-36.
PubMed
13) Pressman PS, Miller BL. Diagnosis and management of behavioral variant frontotemporal dementia. Biol Psychiatry 2014 ; 75 : 574-81.
PubMed
P.217 掲載の参考文献
1) Cushing H. Studies in Intracranial physiology & surgery : the third circulation, the Hypophysis, the Gliomas : the Cameron prize lectures delivered at the University of Edinburgh, October 19-22, 1925. Oxford, 1926.
 
2) Oreskovic D, Klarica M. The formation of cerebrospinal fluid : nearly a hundred years of interpretations and misinter- pretations. Brain Res Rev 2010 ; 64 : 241-62.
 
3) Brinker T, Stopa E, Morrison J, et al. A new look at cerebrospinal fluid circulation. Fluids Barriers CNS 2014 ; 11 : 10.
 
4) Carare RO, Hawkes CA, Weller RO. Afferent and efferent immunological pathways of the brain. Anatomy, function and failure. Brain Behav Immun 2014 ; 36 : 9-14.
PubMed
5) Tokuda T. The emerging concept of the production and absorption of cerebrospinal fluid, and recent progress in the diagnosis and treatment of iNPH. Clin Neurol 2014 ; 54 : 1193-6.
 
6) 日本正常圧水頭症学会 特発性正常圧水頭症診療ガイドライン作成委員会. 特発性正常圧水頭症診療ガイドライン 第2版 メディカルレビュー社, 2011.
 
P.227 掲載の参考文献
1) 認知症疾患治療ガイドライン 2010. 第1章. 認知症の定義, 概要, 経過, 疫学. p1-7.
 
2) Shiga Y, Miyazawa K, et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology 2004 ; 63 : 443-9.
PubMed
3) Rabinovici GD, Wang PN, et al. First symptom in sporadic Creutzfeldt-Jakob disease. Neurology 2006 ; 66 : 286-7.
PubMed
4) Albert ML, Feldman RG, et al. The 'subcortical dementia' of progressive supranuclear palsy. JNNP 1974 ; 37 : 121-30.
 
5) 認知症疾患治療ガイドライン 2010. 第9章 進行性核上性麻痺. p330-6.
 
6) Josephs KA, Duffy JR, et al. Apraxia of speech and nonfluent aphasia : a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol 2008 ; 21 : 688-92.
PubMed
7) Ouchi H, Toyoshima Y, et al. Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Movement Disorders 2014 ; 29 : 238-44.
PubMed
8) 認知症疾患治療ガイドライン 2010. 第10章 大脳皮質基底核変性症. p337-43.
 
9) 渡邉美穂子, 目黒謙一, 他. 呼吸リハビリテーションを施行した慢性閉塞性肺疾患患者における高次脳機能障害の検討 その頻度と特徴について. リハビリテーション医学 2001 ; 38 : 374-81.
 
10) 石垣征一郎, 四郎丸-杉本あずさ, 他. 特集 NCSE (非痙攣性てんかん重積状態) 高齢発症てんかんと認知症の関連. BRAIN AND NERVE : 神経研究の進歩 2015 ; 67 : 563-8.
 
11) プリオン病および遅発性感染症に関する調査研究班. プリオン病診療ガイドライン 2014.
 
12) Atarashi R, Satoh K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 2011 ; 12 : 175-8.
 

(IV) 社会資源の活用

P.239 掲載の参考文献
1) さいたま市. 平成27年度版 さいたま市の介護保険. 東京法規出版, 2015.
 
2) さいたま市. 安心生活のためのシニアサポートセンター (地域包括支援センター). 現代健康出版, 2015.
 
3) 厚生労働省ホームページ http://www.mhlw.go.jp/topics/kaigo/nintei/gaiyo3.html
 
4) さいたま市高齢者介護サービスのご案内
 

書評

最近チェックした商品履歴

Loading...